Entrada Therapeutics Announces First Participant Dosed In Its Phase 1 Clinical Trial Of ENTR-601-44 For The Potential Treatment Of Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics has announced the dosing of its first participant in a Phase 1 clinical trial for ENTR-601-44, a potential treatment for Duchenne Muscular Dystrophy. The company expects to have data from the trial in the second half of 2024.
September 21, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Entrada Therapeutics' initiation of a Phase 1 clinical trial for ENTR-601-44 could potentially impact its stock price. However, results are not expected until the second half of 2024.
The initiation of a Phase 1 clinical trial is a significant milestone for any biotech company, signaling progress in its research and development efforts. However, the impact on Entrada Therapeutics' stock price may be neutral in the short term as results from the trial are not expected until 2024.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100